Skip to content
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • UK
  • Clinic Portal Login
  • +44 (0)20 8068 8176
  • Request Information
  • +44 (0)20 8068 8176
United KingdomUnited Kingdom
  • Part of brands: |
  • Reproductive Health
    • Specialists
      • EndomeTRIO
      • ERA
      • EMMA
      • ALICE
      • CGT
      • PGT-A
      • PGT-A with ploidy
      • EMBRACE
      • PGT-SR
      • PGT-M
      • Infertility Panels
      • POC PORTFOLIO
      • NACE (NIPT)
      • SAT
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
  • User Manual
  • Send a Sample
  • Academy
Genomics Precision Diagnostic > Oncology > Oncology Hereditary Thyroid

Hereditary Thyroid Cancer Precision Panel

Thyroid malignancies are divided into papillary carcinomas (80%), follicular carcinomas (10%), medullary thyroid carcinomas (5-10%), anaplastic carcinomas (1-2%), primary thyroid lymphomas and primary thyroid sarcomas.
Overview
Indication
Clinical Utility
Genes & Diseases
Methodology
References

Overview

  • Thyroid malignancies are divided into papillary carcinomas (80%), follicular carcinomas (10%), medullary thyroid carcinomas (5-10%), anaplastic carcinomas (1-2%), primary thyroid lymphomas and primary thyroid sarcomas. Hereditary thyroid cancer can arise from either follicular cells, known as familial non-medullary thyroid cancer (FNMTC), or from calcitonin-producing C cells, known as familial medullary thyroid cancer (FMTC). The latter may be related to multiple endocrine neoplasia (MEN) IIA or IIB or pure FMTC syndromes. Advances in molecular genetics have helped identify the presence of several familial cancer syndromes with FNMTC, usually papillary and follicular cancers.  
  • Hereditary cancer syndromes are encountered in all medical specialties. Although they account for about 5% of all malignancies. Most hereditary cancers are associated with a “germline mutation” that will be present in every cell of the human body. Identification of patients at risk of inherited cancer susceptibility is dependent upon the ability to characterize genes and alterations associated with increased cancer risk as well as gathering a detailed personal and family history aiding in the identification of the mode of inheritance as well as other family members at risk of suffering from this susceptibility. Most of these genes are inherited in an autosomal dominant fashion.  
  • The Igenomix Hereditary Thyroid Cancer Precision Panel  can be used as a screening and diagnostic tool ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved, and their high or intermediate penetrance. 

Indication

The Igenomix Hereditary Thyroid Cancer Precision Panel is indicated in those cases where there is a clinical suspicion of thyroid cancer alongside family history, presenting with the following manifestations: 

  • Painless, palpable, solitary thyroid nodule 
  • Hoarseness 
  • Parathyroid tumors 
  • Pancreatic tumors: gastrinoma, insulinoma, glucagonoma etc 
    • Diarrhea 
    • Abdominal pain  
    • Hypoglycemia 
    • Hyperglycemia 
  • Anterior pituitary tumors: prolactinoma, somatotropinoma 
  • Headaches 
  • Visual field defects 
    • Pheochromocytoma 
    • Recurrent hypertension 
    • Sweating 
    • Palpitations 
  • Marfanoid phenotype: slender body, long thin extremities, abnormal laxity in joints, pectus excavatum etc 

 

Clinical Utility

The clinical utility of this panel is:  

  • The genetic and molecular diagnosis for an accurate clinical diagnosis of a patient with personal or family history suggestive of hereditary thyroid cancer.  
  • Early initiation of treatment with a multidisciplinary team for appropriate surveillance, surgery, radiation therapy or ablation.  
  • Risk assessment of asymptomatic family members according to the mode of inheritance  
  • Reduce morbidity related to thyroid cancer or morbidity secondary to complications of surveillance and treatment. 
  • Improved pathways from diagnosis to treatment in susceptible population

Genes & Diseases

Methodology

References

See scientific referrals

Dralle, H., Machens, A., & Lorenz, K. (2008). Hereditäre Schilddrüsenkarzinome [Hereditary thyroid cancer]. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen, 79(11), 1017–1028. https://doi.org/10.1007/s00104-008-1558-y 

Guilmette, J., & Nosé, V. (2017). Hereditary and familial thyroid tumours. Histopathology, 72(1), 70-81. doi: 10.1111/his.13373 

Accardo, G., Conzo, G., Esposito, D., Gambardella, C., Mazzella, M., Castaldo, F., Di Donna, C., Polistena, A., Avenia, N., Colantuoni, V., Giugliano, D., & Pasquali, D. (2017). Genetics of medullary thyroid cancer: An overview. International journal of surgery (London, England), 41 Suppl 1, S2–S6. https://doi.org/10.1016/j.ijsu.2017.02.064 

Haugen, B., Alexander, E., Bible, K., Doherty, G., Mandel, S., & Nikiforov, Y. et al. (2016). 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid, 26(1), 1-133. doi: 10.1089/thy.2015.0020 

NCCN Clinical Practice Guidelines in Oncology: Thyroid Carcinoma. Version l.2016. National Comprehensive Cancer Network. (2021). Retrieved 18 February 2021, from https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf. 

 
descargar

Detail description

Download

Request Information


WE GUIDE YOU Fertility Inherited diseases prevention Healthy pregnancy
Click to view our ISO: 15189 accreditation
OUR SERVICES Genetic solutions For patients Sending samples and documentation
ABOUT US About Igenomix Contact User manual Work with us
FOLLOW IGENOMIX
  020 8068 8176 Email us
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
Country
[2024] © Igenomix Privacy policy Quality policy Legal note Cookies policy       Complaints form

Request Information

Copyright 2025 © UX Themes
  • Reproductive Health
    • Specialists
      • EndomeTRIO
      • ERA
      • EMMA
      • ALICE
      • CGT
      • PGT-A
      • PGT-A with ploidy
      • EMBRACE
      • PGT-SR
      • PGT-M
      • Infertility Panels
      • POC PORTFOLIO
      • NACE (NIPT)
      • SAT
  • Diagnostics
  • About us
    • Igenomix Research
    • About Igenomix
  • User Manual
  • Send a Sample
  • Academy
  • WooCommerce not Found
  • Newsletter
  • UK
  • Clinic Portal Login

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

United Kingdom
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.